Lazard Asset Management
USNA icon

Lazard Asset Management’s Usana Health Sciences USNA Stock Holding History

Lazard Asset Management’s Portfolio USNA Stock Details USNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.26M Buy
+72,395
New +$1.44M ﹤0.01% 1090
2025
Q3 		– Sell
-23,201
Closed -$708K – 2337
2025
Q2 		$708K Buy
23,201
+13,128
+130% +$373K ﹤0.01% 1404
2025
Q1 		$271K Buy
10,073
+2,862
+40% +$90.6K ﹤0.01% 1563
2024
Q4 		$258K Buy
7,211
+7,182
+24,766% +$269K ﹤0.01% 1541
2024
Q3 		$1K Sell
29
-842
-97% -$34.6K ﹤0.01% 2217
2024
Q2 		$39K Hold
871
– – ﹤0.01% 1967
2024
Q1 		$42K Hold
871
– – ﹤0.01% 1753
2023
Q4 		$46K Buy
+871
New +$44.1K ﹤0.01% 1907
2023
Q3 		– Sell
-753
Closed -$47K – 2484
2023
Q2 		$47K Buy
+753
New +$48K ﹤0.01% 1857
2022
Q3 		– Sell
-225
Closed -$16K – 2565
2022
Q2 		$16K Buy
+225
New +$16.8K ﹤0.01% 2165
2022
Q1 		– Sell
-658
Closed -$66K – 2539
2021
Q4 		$66K Buy
658
+97
+17% +$9.68K ﹤0.01% 1624
2021
Q3 		$51K Sell
561
-19,737
-97% -$1.9M ﹤0.01% 1680
2021
Q2 		$2.08M Buy
20,298
+8,744
+76% +$878K ﹤0.01% 846
2021
Q1 		$1.13M Sell
11,554
-54,067
-82% -$4.92M ﹤0.01% 886
2020
Q4 		$5.06M Buy
65,621
+11,085
+20% +$857K 0.01% 655
2020
Q3 		$4.02M Buy
54,536
+20,393
+60% +$1.64M 0.01% 635
2020
Q2 		$2.51M Buy
+34,143
New +$2.68M ﹤0.01% 652
2020
Q1 		– Sell
-18
Closed -$1K – 1765
2019
Q4 		$1K Sell
18
-17,246
-100% -$1.27M ﹤0.01% 1500
2019
Q3 		$1.18M Sell
17,264
-28,925
-63% -$1.94M ﹤0.01% 731
2019
Q2 		$3.67M Sell
46,189
-3,070
-6% -$243K 0.01% 655
2019
Q1 		$4.13M Sell
49,259
-58,227
-54% -$6.08M 0.01% 624
2018
Q4 		$12.7M Sell
107,486
-3,681
-3% -$426K 0.02% 353
2018
Q3 		$13.4M Buy
111,167
+12,425
+13% +$1.54M 0.02% 370
2018
Q2 		$11.4M Buy
98,742
+98,469
+36,069% +$10.8M 0.02% 410
2018
Q1 		$23K Buy
+273
New +$21.1K ﹤0.01% 949
2016
Q2 		– Sell
-17,200
Closed -$1.04M – 1106
2016
Q1 		$1.04M Buy
+17,200
New +$1.01M ﹤0.01% 671

Other funds holding USNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Pzena Investment Management
Pzena Investment Management New York $30.8B AUM 11.29% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Lazard Asset Management's USNA Position: Q1 2026 in Review

Lazard Asset Management opened a new position in Usana Health Sciences (USNA) in Q1 2026: 72,395 shares worth $1.26M. The stake represents ﹤0.01% of the portfolio and ranks #1090 among its holdings. This is a return to the name: Lazard Asset Management previously reported a position in USNA as recently as Q2 2025.

Lazard Asset Management first reported a position in USNA in Q1 2016 and has held it in 26 quarters since. The position peaked at $13.4M in Q3 2018. 139 funds tracked by Wall St. Rank hold USNA as of Q1 2026.

  • Lazard Asset Management held 72,395 shares of Usana Health Sciences worth $1.26M as of Q1 2026.
  • Usana Health Sciences was a new Lazard Asset Management position in Q1 2026.
  • Usana Health Sciences made up ﹤0.01% of Lazard Asset Management's portfolio in Q1 2026, its #1090 holding.
  • Lazard Asset Management first reported a position in Usana Health Sciences in Q1 2016 and has held it in 26 quarters since.
  • Lazard Asset Management's Usana Health Sciences position peaked at $13.4M in Q3 2018.
  • 139 funds tracked by Wall St. Rank held Usana Health Sciences as of Q1 2026.

Based on Lazard Asset Management's 13F filing for Q1 2026, filed 15 May 2026.